Ribometrix Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 21

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $12M

  • Investors
  • 13

Ribometrix General Information

Description

Operator of a biotechnology company intended to develop small-molecule therapeutics that modulate ribonucleic acid biology. The company leverages expertise in three-dimensional Ribonucleic acid structural analysis to identify novel small molecules that inhibit the production of disease-associated proteins, proprietary ribonucleic acid structure determination, state-of-the-art ribonucleic acid tools and technologies, and complementary artificial intelligence and machine learning capabilities to directly target and modulate ribonucleic acid biology, enabling researchers to analyze and understand the role that ribonucleic acid structure plays in biological processes and disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 8 Davis Drive
  • Suite 120
  • Durham, NC 27713
  • United States
+1 (919)
Primary Industry
Discovery Tools (Healthcare)
Corporate Office
  • 8 Davis Drive
  • Suite 120
  • Durham, NC 27713
  • United States
+1 (919)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ribometrix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 06-Sep-2023 $12M Completed Pre-Clinical Trials
8. Later Stage VC (Series A1) 26-Sep-2019 Completed Pre-Clinical Trials
7. Early Stage VC (Series A) 13-Nov-2018 Completed Pre-Clinical Trials
6. Seed Round 15-Jun-2018 Completed Clinical Trials - Phase 1
5. Grant 01-Jan-2017 Completed Clinical Trials - Phase 1
4. Debt - General 20-Jun-2016 Completed Startup
3. Grant 01-Jan-2016 Completed Startup
2. Corporate 01-Jan-2015 $100K $100K Completed Startup
1. University Spin-Out 01-Jan-2014 Completed Startup
To view Ribometrix’s complete valuation and funding history, request access »

Ribometrix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1
Series A
Series 1 6,675,574 $0.001000 $1.12 $1.12 1x $1.12 19.75%
To view Ribometrix’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Ribometrix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to develop small-molecule therapeutics that modulate ribonucleic acid biolo
Discovery Tools (Healthcare)
Durham, NC
21 As of 2026

Watertown, MA
 

Bernardsville, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ribometrix Competitors (15)

One of Ribometrix’s 15 competitors is Remix Therapeutics, a Venture Capital-Backed company based in Watertown, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Remix Therapeutics Venture Capital-Backed Watertown, MA
Anima Biotech Formerly VC-backed Bernardsville, NJ
STORM Therapeutics Venture Capital-Backed Cambridge, United Kingdom
Arrakis Therapeutics Venture Capital-Backed Waltham, MA
Biosplice Therapeutics Private Equity-Backed San Diego, CA
You’re viewing 5 of 15 competitors. Get the full list »

Ribometrix Patents

Ribometrix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025120599-A1 Methods of using eif4e inhibitors for treating cancer Inactive 08-Dec-2023
WO-2025101516-A1 Methods of using eif4e inhibitors for treating cancer Inactive 06-Nov-2023
US-20240246918-A1 Compounds and compositions as eif4e inhibitors and the uses thereof Pending 10-Nov-2022
AU-2023375675-A1 Compounds and compositions as eif4e inhibitors and uses thereof Pending 10-Nov-2022
AU-2023375677-A1 Compounds and compositions as eif4e inhibitors and uses thereof Pending 10-Nov-2022 C07D239/90
To view Ribometrix’s complete patent history, request access »

Ribometrix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ribometrix Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Gray Ventures Venture Capital Minority
Amgen Ventures Corporate Venture Capital Minority
Illumina Ventures Venture Capital Minority
M Ventures Corporate Venture Capital Minority
Pappas Capital Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Ribometrix FAQs

  • When was Ribometrix founded?

    Ribometrix was founded in 2014.

  • Where is Ribometrix headquartered?

    Ribometrix is headquartered in Durham, NC.

  • What is the size of Ribometrix?

    Ribometrix has 21 total employees.

  • What industry is Ribometrix in?

    Ribometrix’s primary industry is Discovery Tools (Healthcare).

  • Is Ribometrix a private or public company?

    Ribometrix is a Private company.

  • What is Ribometrix’s current revenue?

    The current revenue for Ribometrix is .

  • How much funding has Ribometrix raised over time?

    Ribometrix has raised $57.5M.

  • Who are Ribometrix’s investors?

    Gray Ventures, Amgen Ventures, Illumina Ventures, M Ventures, and Pappas Capital are 5 of 13 investors who have invested in Ribometrix.

  • Who are Ribometrix’s competitors?

    Remix Therapeutics, Anima Biotech, STORM Therapeutics, Arrakis Therapeutics, and Biosplice Therapeutics are some of the 15 competitors of Ribometrix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process